KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial.

Dean A Fennell, Kayleigh Hill, Min Zhang, Charlotte Poile, Sean Ewings, Essa Y Baitei, Joanna Dzialo, Nada Nusrat, Jan Rogel, Daniel Faulkner, Christian Ottensmeier, Raffaele Califano, Gerard G Hanna, Sarah Danson, Nicola Steele, Mavis Nye, Lucy Johnson, Kim Mallard, Joanne Lord, Calley Middleton, Peter Szlosarek, Sam Chan, Liz Darlison, Peter Wells-Jordan, Cathy Richards, James Harber, Aleksandra Bzura, Jake Spicer, Catrin Pritchard, Tamihiro Kamata, Jens C Hahne, Maymun Jama, Edward J Hollox, Jason F Lester, Jin-Li Luo, Zisen Zhou, Hongji Yang, Huiyu Zhou, Astero Klampatsa, Gareth O Griffiths

Nat Commun 16(1) 6688

PMID40691143
PMCIDPMC12280041
DOI10.1038/s41467-025-61691-4
发表日期2025-07-21
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Leveraging adaptive tumour immunity to control mesothelioma via immune checkpoint blockade is now a standard therapeutic approach. However, the determinants of sensitivity remain elusive. Low non-synonymous mutation burden and programmed death-ligand 1 expression, an abundance of immunosuppressive immune cell infiltration, and 9p21 deletion should all mitigate responses to therapy. To address this knowledge gap, we conducted a double blind, placebo-controlled, randomized phase III trial of the PD1 inhibitor, nivolumab (ClinicalTrial.gov registration: NCT03063450). After 37.2 months of follow-up, the primary endpoint of progression free-survival, but not overall survival was met. The nivolumab response rate was 10.3%, and related grade 3 or above adverse events occurred in 20.4% versus 7.2% for placebo. Progression-free and overall survival were longer in nivolumab-treated responders versus non-responders. In an exploratory multiomic analysis, blinded whole exome, transcriptome and multiplex immune profiling were used to interrogate R- versus NR-subgroups. Non-synonymous and neoantigen mutation burden were no different between groups, however R-mesotheliomas were infiltrated with activated CD8+ T- and CD19+ B-lymphocytes, organised into tertiary lymphoid structures. B-cell infiltration correlated with pro-inflammatory chemokines including IL24 and CCL19. Conversely, epithelial-mesenchymal transition and mitosis were associated with resistance to nivolumab. These findings illuminate features which can be leveraged to advance precision immunotherapy in this rare cancer setting.

KM 提取结果

2 个 Figure · 5 个 KM 面板

进入结果中心
KM Figure4 个面板

Fig. 1

Fig. 1. Interrogating response heterogeneity via blinded multi-omic analysis of R- versus NR-mesotheliomas. A Upper panel. Kaplan-Meier curve showing investigator-reported progression-free survival for nivolumab and placebo treatment groups in CONFIRM. Lower panel. Kaplan-Meier curve showing overall survival (proportion alive) for nivolumab and placebo treatment groups in CONFIRM. B Chest computerised tomography scan of the chest of a patient who exhibited an extreme response to nivolumab over the course of 6 months. C Archival formalin fixed tumour blocks corresponding to patients who received nivolumab and had either a partial response (R) or progressive disease (no response, NR) as their best outcome, were subjected to next generation sequencing of the whole exome or transcriptome. These tissues were also spatially phenotyped using multiplex-immunofluorescence microscopy. Created in BioRender. Fennell, D. ( https://BioRender.com/sq9aqpm .) D Waterfall plot showing the selection of patients from R- vs NR-groups for blinded multi-omic analysis. E Spider plot showing the relative change from baseline for mesotheliomas in the NR- vs R-subgroups. F Kaplan-Meier plots for investigator reported PFS in the translational research cohorts denoted responder and non-responder respectively. These curves are descriptive only and are not formally comparable. G Kaplan-Meier plot for OS in the translational research cohorts denoted responder and non-responder respectively. These curves are descriptive only and are not formally comparable.

A

progression-free survival

Fig. 1 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 2:extreme jump
查看结果
A_2

overall survival

Fig. 1 · Panel A_2

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel A_2 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:extreme upward reversal曲线 2:off origin start曲线 2:extreme upward reversal
查看结果
F

progression-free survival

Fig. 1 · Panel F

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel F 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
G

overall survival

Fig. 1 · Panel G

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel G 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

Fig. 3

Fig. 3. Pro-inflammatory pathway transcriptionally upregulated in R- vs NR-mesotheliomas. A Box plots showing relative chemokine expression corresponding to CCL5, CCL16, CCL17, CCL19, CCL21 and CCL23 transcripts in R- vs NR-mesotheliomas (* indicates a Wilcoxon signed rank test, two-sided p -value equal to or less than 0.05, ** equal to or less than 0.01). Y -axis units correspond to fragments per kilobase of feature per million mapped reads (TPM) normalised counts. The boxplots show the median line and interquartile range (IQR, 25 th −75 th percentiles), with the whiskers extending to the maximum and minimum values. B Boxplots showing Interleukins IL17C, IL23A and IL24 transcripts in R- vs NR-mesotheliomas. The boxplots show the median line and interquartile range (IQR, 25 th −75 th percentiles), with the whiskers extending to the maximum and minimum values. C Scatter plot showing CCL19 versus B lymphocyte lineage as determined by transcriptome deconvolution. Blue dots correspond to R-mesotheliomas and purple to NR (spearman’s rank correlation coefficient= 0.85, p = 1.1 × 10 −7 ). D Scatter plot showing IL24 versus B lymphocyte lineage as determined by transcriptome deconvolution. Blue dots correspond to R-mesotheliomas and purple to NR (spearman’s rank correlation coefficient= 0.66, two-sided p = 0.0006). E Box plot comparing IL24/EMT ratio in R- vs NR- mesotheliomas (*** indicates a significance p < 0.0001). F Receiver operating characteristics plot for the ratio of IL24 transcript levels to EMT enrichment score in R- vs NR-mesotheliomas. AUROC was 0.9. G Left. Box plot showing the relative enrichment of CD8 immune cells in R (blue) vs NR (purple) mesotheliomas deconvoluted using MCP-Counter, Wilcoxon two-sided p = 0.024). This boxplot shows the median line and interquartile range (IQR, 25 th −75 th percentiles), with the whiskers extending to the maximum and minimum values. Right. Scatter plots showing CD8 + T cell enumeration by deconvolution versus multiplex immunofluorescence (mIF) respectively. Spearman’s r = 0.6018, p = 0.002. H Correlation matrix showing a positive (blue) correlation between immune deconvolution algorithms (CIBERSORT, MCP Counter) and multiplex immunofluorescence for CD8 T cell enumeration. I Kaplan Meier curves showing progression free survival of CD8 T cells, EMT, or IL24/CCL19 ratio (dichotomised by the medians) in an independent (MEDUSA) cohort.

I

Progression Free Survival

Fig. 3 · Panel I

quality_warning 待 EXE 对齐 预期 3 条 已提取 2 条

Panel I 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 3 条,实际恢复 2 条曲线 3:very low support曲线 3:extreme jump曲线 3:extreme upward reversal
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 2Fig. 2. Genomic correlates of response to nivolumab in the CONFIRM trial. A Heat map showing the relative burden of driver gene mutations or driver copy number alterations in the R- vs NR-subgroups. B Stacked histogram showing the relative somatic alteration frequency involving 9p21 (left) and BAP1/3p21 (right). BAP1 was not significantly enriched in R versus NR subgroups (NS, not significant). C Upper panel. Somatic copy number alterations (SCNAs) involving amplifications were more frequent in the R- vs NR-subgroups. Lower panel. Copy number alterations specifically affecting DNA damage response genes were not significantly different in the R- vs NR-subgroup. * indicates a Wilcoxon signed rank test two-sided P value equal to or less than 0.05. The boxplots show the median line and interquartile range (IQR, 25 th -75 th percentiles), with the whiskers extending to the maximum and minimum values. D Tumour mutation burden (TMB), clonal or subclonal mutations, intratumour heterogeneity (ITH), neoantigen burden (clonal or subclonal), or somatic copy number alterations (SCNAs). The boxplots show the median line and interquartile range (IQR, 25 th –75 th percentiles), with the whiskers extending to the maximum and minimum values. E Geneset enrichment analysis (GSEA) summary comparing R vs NR transcriptional signature enrichment. F Boxplots comparing geneset enrichment scores (single sample GSEA) in R- vs NR-subgroups. The boxplots show the median line and interquartile range (IQR, 25 th −75 th percentiles), with the whiskers extending to the maximum and minimum values. G Pathway enrichment plot showing inflammatory and chemokine pathway upregulation in R- vs NR-mesotheliomas.
非 KM Figure
Fig. 4Fig. 4. Tertiary lymphoid structures are enriched in nivolumab responders. A Box plot showing a significantly higher number of infiltrating CD8 + T- lymphocytes in R-subgroup mesotheliomas compared with NR. The boxplots show the median line and interquartile range (IQR, 25 th −75 th percentiles), with the whiskers extending to the maximum and minimum values. B Geneset enrichment plot showing germinal centre formation transcriptional signature enrichment in R- vs NR-mesotheliomas. This boxplot shows the median line and interquartile range (IQR, 25 th −75 th percentiles), with the whiskers extending to the maximum and minimum values. C Micrograph showing a representative lymphoid aggregate (TLS) using a CD8, CD4 CD19, PD1, TIM-3, TIGIT multiplex immunofluorescence panel. D Box plots showing the relative TLS abundance in R- vs NR-groups with respect to TLS area, T-cell density both within and outside TLS areas. B-cell density per TLS area and B-cell density within and outside of the TLS areas (* Wilcoxon signed rank test P value < 0.05, ** p < 0.01). The boxplots show the median line and interquartile range (IQR, 25 th −75 th percentiles), with the whiskers extending to the maximum and minimum values. E Scatter plot showing the correlation between %TLS area and OS (r = 0.47, p = 0.02), R is shown in blue and NR in purple. F Endogenous retroviral gene expression showed no difference between R- vs NR-subgroups (NS, not significant). G . Schematic showing the relative balance between stemness (EMT) and inflammation, reflected by chemokine expression and TLS formation. IL24:EMT ratio predicts response, PFS and OS. This figure was created using BioRender. Fennell, D. ( https://BioRender.com/4dwlhk1 ).
非 KM Figure